Business Editors
MIAMI--(BUSINESS WIRE)--June 23, 2000
IVAX Corporation (AMEX:IVX) today announced that the United States Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for isosorbide mononitrate extended-release 60 mg tablets. Isosorbide mononitrate is used to treat angina due to coronary artery disease and is the generic equivalent of Schering Corporation's Imdur(R) 60 mg tablets. IVAX will begin marketing the product in the near future through its wholly-owned subsidiary, Zenith Goldline Pharmaceuticals, Inc.
IVAX Corporation, headquartered in Miami, Florida, is a holding company with subsidiaries engaged in the research, development, manufacturing, and marketing of branded and generic pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets.
Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risk that Zenith Goldline Pharmaceuticals will not launch isosorbide mononitrate extended-release tablets or that its launch will be delayed, and certain other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's 1999 annual report on form 10-KA and its other filings with the Securities and Exchange Commission. Imdur(R) is a registered trademark of Schering Corporation.
COPYRIGHT 2000 Business Wire
COPYRIGHT 2000 Gale Group
Contact
Home
A
Ibuprofen